Phase III, randomised, double-blind, placebo-controlled trial of Neuroaspis plp10 as an adjuvant treatment for relapsing multiple sclerosis: the MINERAL Study

Phase III, randomised, double-blind, placebo-controlled trial of Neuroaspis plp10 as an adjuvant treatment for relapsing multiple sclerosis: the MINERAL Study

Objectives To assess the effectiveness of Neuroaspis plp10 nutritional supplement when added to interferon (IFN)-β treatment in patients with relapsing-remitting multiple sclerosis (RRMS).Design A 30-month phase III multicentre, randomised, double-blind, placebo-controlled trial. Randomisation strat...

Full description

Bibliographic Details
Main Authors: Paolo Preziosa, Maria A Rocca, Georgios Markozannes, Marios C Pantzaris, Paola Valsasina, Nikolaos Grigoriadis, Christos Bakirtzis, Georgios Hadjigeorgiou, Efthimos Dardiotis, George Loucaides, Evangelia Ntzani, Savvas Omorfos, Roberta Messina, Ioannis Patrikios
Format: Article
Language:English
Published: BMJ Publishing Group 2022-11-01
Series:BMJ Neurology Open
Online Access:https://neurologyopen.bmj.com/content/4/2/e000334.full

Internet

https://neurologyopen.bmj.com/content/4/2/e000334.full

Similar Items